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THE MOST IMPORTANT factor in 
making liver transplantation practical 
was the introduction of new immunosuppres-
sant agents of which cyclosporine (CyA) has 
had the greatest impact.! The most common 
cause of hepatic allograft failure still is rejec-
tion, however, OKT3 (Ortho Pharmaceutical, 
Raritan, NJ) is a mouse anti-human T cell 
antibody that in conjunction with azathio-
prine and steroids has been proven effective in 
the reversal of acute rejection in renal trans-
plant recipientsY Recently, two separate 
clinical trials have shown the efficacy of 
OKT3 in treating acute hepatic allograft 
rejection. An interesting observation was that 
the high recurrence rate of rejection previ-
ously seen in other studies after stopping 
OKT3 was not observed with CyA and steroids 
for maintenance.4•5 The purpose of this study 
was to analyze the impact of OKT 3 on reversal 
of acute hepatic rejection and on the overall 
graft and patient survival. 
PATIENTS AND METHODS 
From November 1984 to December 1985, 157 liver 
transplant recipients received a course of OKT3, with at 
least 2 months of subsequent analysis. From August 1983 
to December 1985, 237 other patients underwent hepatic 
transplantation but did not receive OKT3; they served as 
the control group. The following parameters were com-
pared for age, sex, degree of sensitization, degree of HLA 
matching, and graft and patient survival. 
The 157 OKT3-treated patients were stratified in three 
different groups according to the period between trans-
plantation and the initiation of OKT3 therapy. 
Patient Groups 
Group I. The OKT3 treatment was started <10 days 
postoperatively. Sixty-eight patients fell into this category 
and received OKT3 with a median of 6 days. Histologic 
evidence of rejection was noted in 48 (71 %) patients; in 
the remaining 20 patients (29%), however, hepatic biop-
sies showed findings consistent with ischemic (harvest-
ing) injury. Twenty-two of these patients (32%) had 
postoperative renal impairment that precluded the use of 
CyA. Thus, the OKT3 was being used not only to treat 
rejection but also as a CyA-sparing device. 
Group II. OKT3 was administered for 10 to 90 days 
postoperatively in 73 patients with a median of 19 days. 
Sixty-four (88%) had histologic evidence of rejection. The 
causes of graft dysfunction in the remaining 9 patients 
were cytomegalovirus hepatitis in 4 (5%), ischemic injury 
in 4 (5%), and biliary obstruction in 1 (2%). 
Group III. OKT3 therapy was started later than three 
months in 16 patients, after a median of 420 days. All 
patients had histologic evidence of cell-mediated rejec-
tion. although some had findings consistent with chronic 
rejection. These patients had no evidence of ischemic liver 
damage or renal failure. 
OKT) was administered following the precautions pre-
viously described" CyA and steroids were continued 
during the OKT3 therapy, and during this period the CyA 
dose was adjusted in order to achieve therapeutic levels. 
Therapeutic Response 
Liver biopsies were performed before or shortly after 
the onset of OKT3 therapy in 140 (89%) of the patients 
treated with OKT) (Table 1). The biopsy specimens were 
processed and analyzed according to the criteria previ-
ously described.6 Biopsies were repeated at the end of the 
OKT) therapy in 85 (of the 140) patients who had 
biopsies before therapy was initiated. 
The response to therapy was classified as "full" 
response if liver chemistries returned to normal or near 
normal within the first 2 weeks following therapy, as 
partial response if biochemical parameters improved with 
or without histologic improvement, and as no response if 
liver chemistries either did not improve or worsened. 
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Table 1. Results of Hepatic Biopsies in Liver 
Transplant Recipients at the Beginning 
of OKT 3 Therapy 
Group Rejection (%) Ischemia (%) Other (%) 
71 29 0 
II 88 5 7 
III 100* 0 0 
*Many patients had signs of chronic rejection. 
Statistical Analysis 
Fischer's exact test was used to determine statistical 
significance between the treated and control groups. 
Life-table analysis was performed to determine allograft 
as well as patient survival curves. A two-tailed P value of 
<0.05 was considered statistically significant. 
RESULTS 
Fifty-seven of the 157 liver recipients were 
children with an average age of 6.8 ± 5 (SD) 
years, ranging from 6 months to 18 years. The 
average age for the 100 adults was 41 ± 11 
(SD) years, range 19 to 63 years. The overall 
average age for the OKT3 group was 28.6 
years v 23.4 years for the control group. 
Primary transplantation preceeded OKT3 
therapy in 135 (86%) of the patients, and 22 
(14%) underwent retransplantation before 
OKT3 therapy. 
All grafts used for hepatic recipients were 
selected without knowledge of the HLA types 
prior to transplantation. At the HLA A, B, 
and DR loci, the antigens matched averaged 
1.28 ± 0.99 (range 0 to 4, maximum 6) v 
1.10 ± 0.98 for the control group. Neither was 
the degree of presensitization, ie, (panel-reac-
tive antibody, PRA) against a lymphocyte 
panel (PRA), significantly different. The 
mean PRA for the treated group was 11.1 % v 
10.4% for the control group. The incidence of 
hepatic transplantation despite a positive T 
cell cros!t-match was 13% in the OKT3 treat-
ment groups as compared with 17% in the 
control group. 
The overall response rate of the 157 liver 
transplant recipients treated with OKT3 was 
79%; 21 % showed no improvement. When 
these data were stratified to the different 
ESQUIVEL ET AL 
groups, the results shown 10 Table 2 were 
obtained. 
Patient Groups 
Group I. Forty-eight (71 %) of the 68 
patients showed improvement with OKT3 
therapy. In 20 cases, the causes of graft 
dysfunction were ascribed to causes other 
than cell-mediated rejection, namely harvest-
ing injury in 15 and primary graft non function 
in 5. When these 20 patients were eliminated, 
the response rate in this group was only 
slightly better, with 36 patients (76%) of 48 
showing improvement. This observation sug-
gested that OKT3 was a valuable adjunct in 
management by providing immunosuppres-
sion at a crucial time when optimal doses of 
CyA could not be given safely. 
Group II. A therapeutic response to 
OKT3 therapy was noted in 64 (88%) of the 73 
patients. In 9 of the 73 patients causes of graft 
dysfunction other than rejection were identi-
fied: cytomegalovirus hepatitis (4 patients), 
ischemic injury (4 patients) and biliary 
obstruction (1 patient). Omission of these nine 
patients improved the response rate to 94%, 
with 72% having a complete response. There 
were only four (6%) failures in this cleaned-up 
group of 64. 
G roup I II. Eleven (69%) of the 16 
patients showed improvement of the biochem-
ical parameters and 8 had full reversal. The 
failure rate was 31 %. 
Recurrence of Rejection and Impact 
on Retransplantation 
During the period of follow-up to February 
1986, only 25 (20%) of the 125 patients 
Table 2. Response to OKT 3 Therapy and Incidence 
of Retransplantation in Liver Transplant Recipients 
Retrans-
Overall Full Partial None plantation 
Group (n) (%) (nl (%) (nl (%) (n) (%) (n) (%) 
I (n = 68) 48 71 26 38 22 33 20 29 22 32 
II (n = 73) 64 88 50 69 14 19 9 12 9 12 
III (n = 16) 11 69 8 50 3 19 5 31 6 37 
OKT3 IN ACUTE HEPATIC REJECTION 
demonstrating a response to OKT3 -therapy 
experienced further rejection episodes_ The 
recurrent rejection episodes occurred a mean 
of 3.3 months following completion of OKT3 
(range 0.5 to 11.0 months). Sixteen of the 
recurrent rejections were successfully treated 
with high-dose steroids, with return of normal 
hepatic function. The other nine patients sub-
sequently lost their grafts and required 
retransplanta tion. 
The nature of the case selection biased all 
statistics against the OKT3 groups in that the 
drug was used for the sickest patients and for 
those with refractory rejections. Among all 
157 patients treated with OKT3 for graft 
dysfunction, the incidence of retransplanta-
tion was 23.6%, almost identical to the 
favored control group (22.2%). The impact of 
OKT3 on retransplantation was most evident 
in the patients of group II who almost always 
had cell-mediated rejection that was resistant 
to steroid therapy. In these patients, the inci-
dence of retransplantation was only 12%. 
Patients of group III had an ultimate retrans-
plant rate of 37%, whereas the rate in group I 
was 32%. 
IMPACT OF OKT3 ON ALLOGRAFT AND 
PATIENT SURVIVAL 
The graft survival in the control group at 1 
year was 54.9%, whereas in the OKT3-treated 
group it was 64.4%. This difference was statis-
tically significant (P < .01). The I-year graft 
survival in group I and group III was 64.4% 
and 68.8%, respectively, and the difference 
was not statistically different from that of the 
control group. In contrast, the I-year graft 
survival in group II was 76.7%, and this 
difference was very significant (P < .001). 
The results are summarized in Fig 1. 
The patient survival in the control group at 
6 months was 73.6% as compared with 82.9% 
of the OKTrtreated group (P < .OI). The 
6-month recipient survival in group II was 
86.7% (P < .005). Survival was still better in 
the OKT3 group at 1 year (75.1% v 71.6%), 
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Fig 1. life-table analysis of graft survival in groups I 
and II (described in text) v control. 
but this difference was not statistically signifi-
cant (Fig 2). 
DISCUSSION 
The purest conditions for assessment of 
OKT 3 were in patients treated between 10 and 
90 days after OL T (group II). In these recip-
ients, rejection was the cause of graft dysfunc-
tion in almost 90% of cases. 
In contrast, patients who required OKT3 
within 10 days of OLT frequently had other 
causes of graft dysfunction. In this difficult 
group of patients, the diagnosis of rejection 
was difficult to make. The harvesting injury 
often was dominant on histologic examination 
and could mask the findings of rejection. 
Nevertheless, a significant number of patients 
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Fig 2. Life-table analysis of patient survival of the 
OKT .-treated group as compared with the control 
group. 
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without an unequivocal diagnosis of rejection 
benefited from OKT3 therapy. In these recip-
ients who also had a high incidence of renal 
impairment, the dose of Cy A could be reduced 
to allow recovery of the kidneys while effec-
tive immunosuppression was maintained with 
OKT3• OKT3 was also effective in a surprising 
number of patients treated ;:::3 months after 
transplantation (group III), even though 
many had signs of chronic rejection on histo-
logic examination in addition to acute rejec-
tion. OKT3 is probably not effective in 
patients with irreversible hepatic damage 
from the kind of chronic rejection that 
destroys small bile ducts and obliterates the 
arterial supply. 
The final analysis of a new immunosuppres-
sive agent is the impact of that drug on overall 
graft and patient survival. The present investi-
gation showed that OKT3 improved graft sur-
vival and 6-month patient survival even 
though the OKTrtreated recipients were 
those with the greatest rejection and other 
difficulties. The patient survival of the OKT3-
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treated group at I year was not different from 
that of the control group. 
SUMMARY 
OKT3 was an effective immunosuppressant 
agent in patients with acute cell-mediated 
allograft rejection that had not responded to 
initial steroid therapy. OKT3 was also valu-
able for treating patients with early hepatic 
graft dysfunction caused by other factors than 
rejection. In such recipients, the doses of CyA 
can be greatly reduced, allowing recovery of 
frequently damaged kidneys while maintain-
ing effective immunosuppression. 
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